---
title: "Silo Pharma Expands Into AI Agent Market With Qwikagents Platform Acquisition; Stock Down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283789428.md"
description: "Silo Pharma, Inc. has expanded into the AI market by acquiring Qwikagents.ai, an AI platform for autonomous agents. This move aims to tap into the projected $47-$53 billion AI agent market by 2030. CEO Eric Weisblum believes this diversification will leverage high-growth tech opportunities. Silo Pharma focuses on psychiatric disorders and chronic pain, with its stock closing at $0.56, down 8.13%, and further declining to $0.52 in overnight trading."
datetime: "2026-04-23T08:15:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283789428.md)
  - [en](https://longbridge.com/en/news/283789428.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283789428.md)
---

# Silo Pharma Expands Into AI Agent Market With Qwikagents Platform Acquisition; Stock Down

(RTTNews) - Silo Pharma, Inc. (SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, announced a strategic expansion into AI technology as a second line of business, following its recent purchase of Qwikagents.ai's assets, an AI platform designed to support the deployment of autonomous AI agents.

Qwikagents.ai is designed to provide businesses and individuals with dedicated AI agents for executing tasks such as research, content generation, scheduling, and workflow automation.

The firm noted that, according to MarketsandMarkets.com, the multi-billion-dollar AI agent market is projected to reach $47 and $53 billion by 2030 which is roughly 6 times more growth in 4 years.

Silo Pharma's therapeutic focus is on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.

"We expect that Silo's diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy," said Eric Weisblum, Chief Executive Officer.

Silo Pharma's primary therapeutic development portfolio includes SPC-15 for Post-Traumatic Stress Disorder or PTSD, SP-26 for Fibromyalgia and Chronic pain.

SILO has traded between $0.22 and $1.18 over the last year. The stock closed Wednesday's trade at $0.56, down 8.13%.

In the overnight market, SILO is down 7.67% at $0.52.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [SILO.US](https://longbridge.com/en/quote/SILO.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [OPENAI: OPENAI IS COLLABORATING WITH AI LEAP, THE UNIVERSITY OF TARTU, AND STANFORD](https://longbridge.com/en/news/287035011.md)
- [AI face is taking over — and driving plastic surgeons crazy](https://longbridge.com/en/news/286641783.md)
- [Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation | AMIX Stock News](https://longbridge.com/en/news/286772951.md)
- [Jack Antonoff tells people who are making AI art to 'drive right off that cliff'](https://longbridge.com/en/news/286592426.md)
- [How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here](https://longbridge.com/en/news/286786866.md)